Difference between revisions of "Migraine"
Jump to navigation
Jump to search
m (Protected "Migraine" ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
|||
| (2 intermediate revisions by one other user not shown) | |||
| Line 18: | Line 18: | ||
Requires clonidine as prophylaxis (preventative medication) | Requires clonidine as prophylaxis (preventative medication) | ||
| + | |||
| + | Monoclonal antibodies are used for migraine prophylaxis. In the UK, erenumab (aimovig), fremanezumab (ajovy), galcanezumab (emgality) are the monoclonal antibodies licensed for use. | ||
====Acceptable==== | ====Acceptable==== | ||
| − | Uses pizotifen or beta-blocker as prophylaxis | + | Uses pizotifen (Sanomigran) or beta-blocker as prophylaxis |
| Line 29: | Line 31: | ||
==Version== | ==Version== | ||
| − | Version 1, Edition | + | Version 1, Edition 2 |
====Date of Last Update==== | ====Date of Last Update==== | ||
| − | + | ||
| + | 1 June 2016 | ||
Latest revision as of 09:48, 26 July 2024
Contents
Acceptability at Recruitment
QUALIFIED
Acceptability at CT / Work-Up
QUALIFIED
Individual at Risk
Donor
Explanation of Condition
Intermittent headaches associated with nausea and visual phenomena (aura), such as zig-zag lines or halos.
See also Migraine
Guidance
Unacceptable
Severe, having more than two attacks per month
Requires clonidine as prophylaxis (preventative medication)
Monoclonal antibodies are used for migraine prophylaxis. In the UK, erenumab (aimovig), fremanezumab (ajovy), galcanezumab (emgality) are the monoclonal antibodies licensed for use.
Acceptable
Uses pizotifen (Sanomigran) or beta-blocker as prophylaxis
Discuss with medical officer if unclear.
Pseudonyms or Related Conditions
Version
Version 1, Edition 2
Date of Last Update
1 June 2016
